The real-world occurrence rate of non-breast cancer-specific death (non-BCSD) and its impact on patients with breast cancer are poorly recognized. METHODS: Women with resectable breast cancer from 1990 to 2007 in the Surveillance, Epidemiology, and End Results database (n 5 199,963) were analyzed. The outcome events of breast cancer were classified as breast cancer-specific death (BCSD), non-BCSD, or survival. Binary logistics was used to estimate the occurrence rates of non-BCSD and BCSD with different clinicopathological factors. The Gray method was used to measure the cumulative incidence of non-BCSD and BCSD. The ratio of non-BCSDs to all causes of death and stacked cumulative incidence function plots were used to present the impact of non-BCSD on overall survival (OS). Models of Cox proportional hazards regression and competing risk regression were compared to highlight the suitable model. RESULTS: There were 12,879 non-BCSDs (6.44%) and 28,784 BCSDs (14.39%). The oldest age group (>62 years), black race, and a single or divorced marital status were associated with more non-BCSDs. With adjustments for age, a hormone receptor-positive (HoR1) status was no longer related to increased non-BCSDs. In patients with grade 1, stage I disease and an HoR1 status as well as the oldest subgroup, a great dilution of non-BCSD on all causes of death could be observed, and this led to incorrect interpretations. The inaccuracy, caused by the commonly used Cox proportional hazards model, could be corrected by a competing risk model. CONCLUSIONS: OS was largely impaired by non-BCSD during early breast cancer. For some future clinical trial planning, especially for the oldest patients and those with HoR1 breast cancer, non-BCSD should be considered a competing risk event.
INTRODUCTION
Overall survival (OS) is considered the most important endpoint for demonstrating a direct clinical benefit from new treatment methods up for approval by the Food and Drug Administration. 1 The Herceptin adjuvant therapy trials led to an improvement of OS, [2] [3] [4] [5] [6] [7] [8] whereas aromatase inhibitor (AI) trials and ovarian function-suppression trials failed to show an improvement in OS, with an improvement seen only in disease-free survival (DFS). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Therefore, the upfront use of AIs as adjuvant therapy for breast cancer is still controversial. 20 The reason that an improvement in DFS cannot be translated into an improvement in OS is undefined. Cuzick 21 summarized AI trials and found that efficacy results for AIs could be confounded by non-breast cancer-specific death (non-BCSD). With increasing rates of early detection resulting from mammography screening programs and improvements in adjuvant therapy, breast cancer patients who are expected to survive breast cancer are at a greater risk of non-BCSD. OS will be diluted by other causes of death. [22] [23] [24] Cuzick doubted whether OS could be used to correctly interpret the real outcomes. However, the Standardized Definitions for Efficacy End Points (STEEP) system proposed standardized definitions for effective endpoints in adjuvant breast cancer trials but did not issue and modify the definition of OS. 25 OS based on the absolute risk of death, which does not take into account competing causes of death, may not be the optimal measure for accessing the outcomes of breast cancer. Therefore, a crude specific survival model based on competing risk models was encouraged to describe real-world disease and to help clinicians and patients approach the treatment decision. 26 In this large population-based study, a detailed distribution of non-BCSD was analyzed through a comparison of 2 models of Cox proportional hazards regression and competing risk regression to define an optimal statistical method for breast cancer.
MATERIALS AND METHODS

Inclusion and Exclusion Criteria
The Surveillance, Epidemiology, and End Results (SEER) database is collected and released annually to reflect the latest updated information. We received permission to access the research data (reference number 10263-Nov2015). The study was approved by the ethics committee of Zhejiang University Jinhua Hospital. SEER*Stat software was used to identify patients diagnosed with breast cancer from January 1990 to December 2007. Patients diagnosed after 2007 were excluded to ensure an adequate duration of follow-up. The year and age at diagnosis, sex, race, marital status, histological type, differentiation grade, TNM classification (6th edition), estrogen receptor (ER) status, progesterone receptor (PR) status, radiotherapy administration status, survival (in months), and cause of death were retrieved from the SEER database. The specific inclusion criteria were as follows: 1) the International Classification of Diseases for Oncology (3rd edition) site record was limited to breast cancer (C500-C506, C508, and C509); 2) the International Classification of Diseases for Oncology (3rd edition) histological type was limited to 8500/3, 8520/3, 8521/3, 8522/3, and 8524/ 3; 3) there were no distant metastases; and 4) the age at diagnosis was 20 to 70 years. The limit of 70 years was selected because most clinical research sets the age limit at 70 years. The exclusion criteria were as follows: 1) patients with a lack of documentation of their race, marital status, or age at diagnosis were excluded; 2) patients with multiple primary tumors were excluded to make the analyses of cancer-specific survival more accessible; 3) patients surviving less than 1 month were excluded; and 4) patients were excluded if the cause of death was recorded as "state DC [death certificate] not available or state DC available but no COD [cause of death]" (for detailed inclusion and exclusion criteria, see the online supporting information).
Variable Declaration
All of the cases were regrouped according to the 7th edition of the American Joint Committee on Cancer TNM staging system. Race was classified as white, black, or other. The hormone receptor (HoR) status of the tumors was stratified into 2 categories: hormone receptor-positive (HoR1; ER-positive/PR-positive, ER-negative/PR-positive, or ER-positive/PR-negative) and hormone receptornegative (HoR-; ER-negative/PR-negative). The cutoff ages of 40 and 62 years were determined with the X-tile program. 27 The age of 40 years was based on breast cancer-specific death (BCSD; Supporting Fig. 1 [see online supporting information]), and the age of 62 years was based on non-BCSD (Supporting Fig. 2 [see online supporting information]) because non-BCSD frequently occurred for the oldest patients and BCSD more frequently occurred for the youngest patients. Age was reclassified as youngest (<40 years), older (40-62 years), or oldest (>62 years). The marital status was reclassified as married, single, or divorced.
Statistical Analysis
Binary logistics was used to analyze the non-BCSD occurrence rate among all variables. The multivariate analysis included the variables of stage and HoR status rather than the variables of T and N classification and ER/PR status because these were confounded and overlapped. Non-BCSD was the death due to causes other than cancer. The 5-and 10-year non-BCSD rates were calculated with the Kaplan-Meier method, with the ratio of non-BCSD to all causes of death used to estimate the impact of non-BCSD on OS.
When the cumulative incidence of BCSD was estimated with the Gray method, 28 non-BCSD was the competing event (and vice versa). The cumulative incidence of all causes of death was estimated with the Kaplan-Meier method. Stacked cumulative incidence function plots were used to describe specific real-world causes of death. 29 The hazard ratio (HR) of variables for all causes of death was estimated with the Cox proportional hazards model, and the subdistribution hazard ratio (SHR) of variables for cause-specific death was estimated with the Fine-Gray proportional hazards model for the subdistribution. 30 The Gray method, the Kaplan-Meier plots, and the stacked cumulative incidence plots were developed with the cmprsk and survival packages in R software (http:// www.r-project.org/). The Cox model and the competing regression model (the Fine-Gray model) were developed with Stata/SE 12.0 statistical software (StataCorp LP, College Station, Texas). When the 2-sided P value was less than .05, the difference was considered statistically significant.
RESULTS
We identified 199,963 eligible patients with resectable breast cancer. The endpoint date of follow-up was November 2013, and the median follow-up duration was 112 months (range, 1-287 months). In total, 12,879 patients (6.44%) and 28,784 patients (14.39%) suffered non-BCSD and BCSD, respectively (79.16% of the patients were considered as censored events). The median age of the patients was 53 years (interquartile range, 20-70 years). According to the Kaplan-Meier method, the 3-, 5-, and 10-year probabilities of non-BCSD were 1.24%, 2.24%, and 5.39%, respectively; the 3-, 5-, and 10-year probabilities of BCSD were 4.79%, 8.41%, and 14.17%, respectively; and the 3-, 5-, and 10-year probabilities of all causes of death were 5.97%, 10.47%, and 18.80%, respectively.
Association of Patient and Tumor Characteristics With Non-BCSD
The univariate logistic analysis showed that more non-BCSD was associated with older or oldest age, black race, a single or divorced marital status, and no administration of radiotherapy. Such factors tended to be retained in the multivariate model; the results showed that age, race, and marital status were the most predominant independent prognostic factors of non-BCSD (Table 1 ). An HoR1 tumor was no longer associated with non-BCSD after adjustments for age. The administration of radiotherapy was still an independent prognostic factor with fewer nonBCSDs even after adjustments for age, race, and marital status ( Table 1) .
The other causes of death are listed in detail in Table  2 . The leading cause of death was heart disease. Respiratory disease, cerebrovascular diseases, diabetes, and liver disease were also important causes of non-BCSD. The record code of "state DC [death certificate] not available or state DC available but no COD [cause of death]" had a misclassification error. Because patients registered with this code were associated with an advanced stage, most of them might have died of breast cancer (data not shown). More patients died of heart disease and cerebrovascular diseases in the no-radiotherapy subgroup versus the radiotherapy subgroup (Table 2) . The Gray method showed that a higher cumulative incidence of non-BCSD was related to the following characteristics: oldest age (Fig. 1A) , black race (Fig. 1B) , divorced status (Fig. 1C) , no radiotherapy (Fig. 1D) , and HoR1 status ( Fig. 2A) . The univariate analysis showed that age, marital status, histological type, differentiation grade, stage, radiotherapy administration, and HoR status were associated with non-BCSD ( Table 3 ). The results of the univariate analysis were used to guide variable selection for the multivariate analyses, which showed that race, age, marital status, and radiotherapy administration could independently predict the cumulative incidence of non-BCSD (Table 3) Table 3 .
Comparison of 2 Models: Cox Proportion Hazards Regression and Competing Risk Regression
A Cox proportional hazards model showed that the oldest patients had a worse prognosis than the youngest ones. The HR of all causes of death was 1.22 (95% CI, 1.18-1.26) for the oldest patients versus the youngest patients. The cumulative incidence of all causes of death for different age groups, based on the Kaplan-Meier method, is shown in Figure 2D . The HR of all causes of death for HoR1 patients (vs HoR-patients) was 0.56 (95% CI, 0.54-0.57), and the Kaplan-Meier curves of all causes of death for HoR-and HoR1 tumors crossed at approximately 300 months (Fig. 2C) . Detailed results from the univariate and multivariate analyses for all causes of death based on the Cox proportional hazards model are shown in Supporting Table 1 (see online supporting information).
However, there were different outcomes according to the competing risk regression model. The oldest patients had a lower mortality rate than the youngest patients (SHR, 0.53; 95% CI, 0.51-0.55). The curves of the cumulative incidence of BCSD, based on the Gray method, never crossed for HoR-and HoR1 tumors ( Fig.  2A ), whereas the BCSD curves for the oldest subgroup separated more obviously (Fig. 2B ). The SHR of BCSD (vs an HoR-status) was 0.44 (95% CI, 0.43-0.45) without adjustments. Detailed results of the univariate and multivariate analyses for BCSD based on the competing risk regression model are shown in Supporting Table 2 (see online supporting information).
Original Article
Impact of Non-BCSD on OS
The 5-and 10-year probabilities of non-BCSD and all causes of death were analyzed with a Kaplan-Meier failure function ( Table 4 ). The ratio of BCSDs to all causes of death was higher than 0.5 for patients with well-differentiated, stage I tumors. The ratio was 0.3 for the HoR1 subgroup. In the subgroups with poor OS (eg, patients with stage III and HoR-tumors), the ratio was lower than 0.2 (Table 4) . A stacked cumulative incidence function plot was used to generate the crude cause-specific risk of death. For the HoR1 subgroup, the risk of BCSD was exceeded by the risk of non-BCSD until approximately 250 months of follow-up (Fig. 3A) . For the oldest subgroup, the risk of BCSD was exceeded by the risk of non-BCSD at the beginning of follow-up (Fig. 3B) . For the stage I subgroup (Fig. 3C ) and the well-differentiated subgroup (Fig. 3D) , the risk of non-BCSD always exceeded the risk of non-BCSD.
DISCUSSION
It is clear that age is the most predominant factor affecting non-BCSD. For very old patients with breast cancer, the competing risk events of death will decrease the risk of BCSD, so the cumulative incidence of BCSD, based on the Gray method (which considers the presence of competing risk events), will be underestimated. After an adjustment for age, the HoR status was no longer associated with non-BCSD. The administration of radiotherapy was associated with better non-BCSD. Non-BCSD diluted all causes of death for patients with stage I and welldifferentiated tumors and for the oldest and HoR1 subgroups. If the OS-based Kaplan-Meier method is chosen as the endpoint of interest, an incorrect interpretation will be made because the youngest patients had a better prognosis than the oldest patients, and the curves for HoR1 and HoR-tumors crossed. The confounding will be clarified if a competing risk model is applied.
In the Herceptin adjuvant therapy trials, which mostly included patients with poorly differentiated tumors, an advanced stage, and an HoR-status, positive outcomes with DFS and OS were observed. [2] [3] [4] [5] 7, 8, 31, 32 However, in adjuvant AI endocrine therapy trials, only the survival measure of DFS, rather than OS, had a positive outcome. In addition, in AI endocrine therapy trials, most postmenopausal patients with well-differentiated tumors, at earlier stages, and with HoR1 breast cancers were included. 9, 11, [14] [15] [16] [17] 19, 33 According to the current study, in patients with poorly differentiated tumors, an advanced stage, and an HoR-status (characteristics similar to those in the Herceptin trials), the survival analysis was less likely to be diluted by non-BCSD. In contrast, similarly to the AI trials, patients with well-differentiated tumors, at an earlier stage, and with an HoR1 status experienced a greater impact from non-BCSD. Therefore, non-BCSD can be an important explanation for why Herceptin rather than AIs can improve OS.
In the AI-related trials, non-BCSD represented more than 30% of deaths. Time trends in the publications reporting outcomes from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trials showed that the proportion of non-BCSDs/deaths from all causes increased from 39.5% after a median follow-up of 33 months to 41.6% after a median follow-up of 100 months. 10, 15 With the increasing frequency of non-BCSD, the competition derived from non-BCSD will definitely be more obvious. In an AI trial, once a negative outcome for the 5-year OS rate is shown, a positive outcome will be more difficult to observe with prolonged follow-up. Alternatively, the outcome will be confounded by rescue crossover treatments. 13 Another issue is the impact of endocrine therapy on all causes of death. In the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) study, the results revealed that the risk of death caused by endometrial cancer increased by 0.3% in the group continuing tamoxifen for 10 years versus the group stopping after 5 years. 34 However, in the current study, non-BCSD increased in the HoR1 subgroup, but this increase was no longer significant after adjustments for age. That is, endocrine therapy may not result in an increase in non-BCSD.
In our study, the administration of radiotherapy was associated with fewer non-BCSDs. In addition, heart disease and cerebrovascular disease were decreased among the patients administered radiotherapy. An MA.27 competing risk analysis also showed that the administration of radiotherapy was associated with less non-BCSD and especially less cardiovascular disease-related death; this reflects the better overall health of those receiving radiotherapy. 35 De Glas et al 22 reanalyzed the MA.17 trial with competing risk models, which showed that compared with a placebo, letrozole endocrine therapy after 5 years of tamoxifen therapy could not improve OS for postmenopausal women. Because there was no upper age limit in the study (and thus many older patients were enrolled), OS was associated more with baseline heart disease, with less than 40% of deaths associated with breast cancer. OS was diluted by non-BCSD. To observe enough BCSD events and a positive outcome, a larger sample might need to be recruited. The ATLAS trial, a similar study enrolling more patients (12,894 women), showed continuing tamoxifen to 10 years could lead to a improved OS. 34 Two studies using SEER data have assessed breast cancer outcomes while considering competing causes of death. In the first study, 438,015 patients with all stages of breast cancer were analyzed from 1973 to 2000. In agreement with our results, age and race were important factors related to non-BCSD. Higher rates of obesity in black patients might have contributed to unfavorable outcomes. 24 Because the ER and PR status have been recorded only since 1990, most patients did not have a record of their HoR status. The extent of disease, the tumor size, and the lymph node status were not provided, so the TNM stage could not be obtained, and instead the staging was classified as in situ, localized, regional, or distant. The association of non-BCSD with the stage and HoR status was not confirmed in that study. 24 Alternatively, the sequence of primary malignant tumors was included in the study and was found to be a leading other cause of death. 24 In our study, the patients with a sequence of primary malignant tumors were excluded. In the second study, 51,246 patients with special stages of breast cancer (T1a-1b N0M0) from 1998 to 2001 were analyzed. The 10-year probabilities of other causes of death and BCSD were 20% and 4%, respectively. 23 Patients with radiotherapy and ER-negative tumors were less likely to die as a Figure 1 . Effects of (A) age, (B) race, (C) marital status, and (D) the administration of radiotherapy on non-BCSD and BCSD according to the Gray method. (A) The youngest breast cancer patients (<40 years old) were used as the reference; the oldest patients (>62 years old) and the older patients (41-62 years old) had more non-BCSDs with SHRs of 2.75 (95% CI, 2.47-3.07) and 11.63 (95% CI, 10.44-12.97), respectively (P < .001), and had fewer BCSDs with SHRs of 0.58 (95% CI, 0.56-0.59) and 0.53 (95% CI, 0.51-0.55), respectively (P < .001). (B) Black patients had the most non-BCSDs (SHR, 1.48; 95% CI, 1.41-1.56; P < .001). Other races had the least non-BCSDs (SHR, 0.68; 95% CI, 0.63-0.73; P < .001). Black patients had more BCSDs (SHR, 1.92; 95% CI, 1.86-1.98; P < .001). White race was used as the reference. (C) Divorced women and unmarried women had more non-BCSDs with SHRs of 2.12 (95% CI, 2.04-2.20; P < .001) and 1.26 (95% CI, 1.20-1.33; P < .001), respectively. Divorced women and unmarried women had more BCSDs with SHRs of 1.33 (95% CI, 1.28-1.37; P < .001) and 1.22 (95% CI, 1.18-1.28; P < .001), respectively. Married women were used as the reference. (D) With the administration of radiotherapy, there were fewer non-BCSDs (SHR, 0.69; 95% CI, 0.67-0.72; P < .001). With the administration of radiotherapy, there were fewer BCSDs (SHR, 0.77; 95% CI, 0.75-0.79; P < .001). BCSD indicates breast cancer-specific death; CI, confidence interval; non-BCSD, non-breast cancer-specific death; SHR, subdistribution hazard ratio.
result of non-BCSD; that result is consistent with ours. The main aim of that study was to investigate the impact of variables on BCSD, so further stratified analysis was not performed to confirm the association between non-BCSD and the HoR status or age at diagnosis.
The Cox proportional hazards model showed that OS for the youngest breast cancer patients was associated with a lower probability of all-cause death in comparison with the oldest patients. However, in the competing risk model, there was a completely different result: the youngest breast cancer patients had poor survival outcomes in comparison with the oldest patients. This contradictory result can be clearly explained by the stacked plots. As shown in the stacked cumulative incidence function plots, there was a dramatically increasing risk of death in the oldest group in the later period of the studies, which mainly resulted from higher non-BCSD rates. The proportional hazards distribution might more clearly explain the controversial argument about whether the youngest breast cancer patients have worse survival. 36 When OS calculated with the Kaplan-Meier method was used to describe the outcome, patients with HoR1 breast cancer had better outcomes than HoR-patients until 300 months after the diagnosis. The curves of all causes of death with respect to the HoR status crossed in our study. Jatoi et al 37 also found that the hazard of HoR1 breast cancer would be lower 6 years rather than 8 years after the diagnosis according to the SEER data. The Prospective Study of Outcomes in Sporadic and Hereditary Breast Cancer (POSH) showed that the 5-year OS rate for young patients with ER-positive tumors was higher than that for patients with ER-negative tumors; however, the OS curves for ER-positive tumors and ERnegative tumors crossed 8 years after the diagnosis. 38 Hahnel and Spilsbury 39 found that ER-positive patients had worse OS 5 years after their diagnosis according to singleinstitution data. With a competing risk method (the Gray method) used to describe the outcome, the failure curves of HoR did not cross. Moreover, a continuously increasing risk of non-BCSD was observed in the HoR1 subgroup. However, in our study, the BCSD curves with an HoR1 status never crossed because the BCSD rate of HoR1 patients did not increase significantly over time. If we take no account of competing risk presentation in generating curves of all causes of death according to the Kaplan-Meier method, such curves should be affected more by the cumulative incidence of non-BCSD than the cumulative incidence of BCSD, and this should lead to the crossing of curves for all causes of death for HoR1 and HoR-patients. Inevitably, OS will be diluted by non-BCSD. OS, related to an incorrect interpretation, will be corrected with the competing risk regression method, especially for the oldest subgroup; the probability of the crossing of the curves of HoR1 and HoR-patients will be much smaller. De Glas et al 22 also found that in studies of older patients with HoR1 breast cancer, the absolute risk of all causes of death, based on a Cox proportional hazards model, could be overestimated, and a competing risk regression model should be used instead.
A non-BCSD event is a nonnegligible competing risk in breast cancer. However, the competing risk estimate might lead to overcompeting in some situations. Then, the question arises whether the Cox model or the subdistribution proportional regression model (competing risk) should be chosen as the rational method. This is a significant issue to be addressed when clinical trials are being designed. Both non-BCSD and overcompeting should be addressed carefully when survival is being estimated. It is more rational to present the real world of breast cancer death when one is analyzing BCSD according to the competing risk method. For breast cancer, the competing risk model might be more applicable to old patients with well-differentiated, HoR1, and early-stage cancer.
Our study has several potential limitations. Retrospective analyses always carry the risk of various biases. However, by using a large sample, our study minimized potential biases and was associated with a high degree of power. Moreover, there is no record of the human epidermal growth factor receptor 2 status in the SEER database before 2010, partly because of the lack of attention paid to molecular biology in earlier years. Patients with second primary tumors were excluded in some instances. Treatment-related secondary tumors will occur (eg, lymphoma and leukemia with chemotherapy and endometrial cancer with endocrine therapy). Deaths caused by a second primary cancer were defined as other causes of death. In the STEEP system, because second primary tumors are partly related to treatment and distant recurrences of breast cancer may be misdiagnosed as a second primary In well-differentiated tumors, the risk of non-BCSD was greater than the risk of BCSD at any time. The curves for specific death were based on the Gray method, and the curves for all causes of death were based on the Kaplan-Meier method. BCSD indicates breast cancer-specific death; HoR, hormone receptor; HoR1, hormone receptor-positive; non-BCSD, non-breast cancer-specific death.
cancer, the second primary tumors were defined as OS events directly. 25 Therefore, there are some mistakes regarding the registration of the cause of death in the SEER system. To minimize the mistakes, the detailed cause of death was verified in the current study.
To the best of our knowledge, this is first large study focusing on real-world non-BCSD and its vital impact on survival analysis. We comprehensively analyzed the non-BCSD distribution of patients with respect to tumor factors. In patients with resectable breast cancer, the incorrect interpretation yielded by Cox models might misguide physicians, patients, and policymakers. There was a predominant impact of non-BCSD on OS for the grade 1, stage I, HoR1, and oldest subgroups. The impact of non-BCSD on OS should be considered in future clinical trials, in which BCSD, based on a competing risk model, should be an alternative endpoint instead of always using traditional OS.
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